Huminsulin Normal Kwikpen (Insulin Human)

Huminsulin Normal Kwikpen is indicated for the management of diabetes that requires insulin replacement. It is used in both type 1 and type 2 diabetes mellitus and can be employed as basal insulin therapy or in combination with rapid‑acting insulins.

• Basal insulin replacement in type 1 diabetes mellitus.
• Adjunct to oral antidiabetic agents in type 2 diabetes mellitus.
• Part of a basal‑bolus insulin regimen.
• Management of hyperglycaemia when diet and exercise are insufficient.
• Use during periods of increased insulin demand (e.g., illness, pregnancy).

• Insulin human in Huminsulin Normal Kwikpen binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling pathways that promote glucose uptake, stimulate glycogen synthesis, and suppress hepatic gluconeogenesis, thereby lowering blood glucose concentrations.

Huminsulin Normal Kwikpen may cause a range of adverse reactions. Most are mild and reversible, while others require immediate medical attention.

Common

• Hypoglycaemia (low blood sugar).
• Injection‑site pain, redness or swelling.
• Lipodystrophy (localized fat loss or accumulation).
• Weight gain.
• Mild allergic skin reactions.

Serious

• Severe hypoglycaemia with loss of consciousness.
• Anaphylactic or systemic allergic reactions.
• Acute insulin allergy with urticaria or angioedema.
• Persistent hypokalemia.
• Severe injection‑site infection.

Before using Huminsulin Normal Kwikpen, patients should be aware of several safety considerations. Proper assessment and monitoring help minimise risks.

• Verify blood glucose levels before each injection to avoid hypoglycaemia.
• Adjust dose during illness, surgery, or changes in diet and activity.
• Use caution in patients with renal or hepatic impairment.
• Monitor for signs of allergic reactions, especially after the first dose.
• Do not share pens; use a new needle for each injection.
• Store the pen according to manufacturer instructions and discard after the indicated period.

Huminsulin Normal Kwikpen can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Other rapid‑acting insulins or insulin analogues administered simultaneously.
• Beta‑blockers that may mask hypoglycaemia symptoms.
• MAO‑inhibitors that can potentiate insulin’s glucose‑lowering effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) – risk of additive hypoglycaemia.
• Corticosteroids – may increase insulin requirements.
• Diuretics, especially thiazides – can affect blood glucose levels.
• Alcohol – may potentiate hypoglycaemia, particularly when taken on an empty stomach.